Health Care More | | | Editor

Immunotherapy promising for cancer

  • Follow Health

While clinical trials are still ongoing and there are many different approaches, using the immune system to target cancer and block the “checkpoints” that halt the immune response are already showing results, a researcher at Georgia Regents University Cancer Center said.

Back | Next
Dr. Esteban Celis, cancer vaccine initiative director at Georgia Regents University Cancer Center, answers a Twitter question on the promise of immunotherapy.  JON-MICHAEL SULLIVAN/STAFF
Dr. Esteban Celis, cancer vaccine initiative director at Georgia Regents University Cancer Center, answers a Twitter question on the promise of immunotherapy.

During a Twitter chat on Wednesday sponsored by the American Association for Cancer Research, Dr. Esteban Celis answered questions on behalf of the organization. The opportunity attracted many of the top cancer centers in the country, all eager to talk about the promise of immunotherapy. Not all of the approaches work the same, Celis tweeted. “Some (Yervoy) take brakes off the immune system’s natural cancer-fighting ability,” he wrote. “Some (Provenge, Proleukin) increase immune cells’ killing power; some (Gazyva) flag cancer cells for destruction.”

GRU has clinical trials on a number of approaches to defeating the “checkpoints” that tumors exploit to evade the immune system and many of the other researchers agreed that it is key to making the immune system recognize and attack tumors. But it will probably be done in combination, Celis wrote.

“Immunotherapy is most likely not going to replace chemo, but work in concert with it,” he tweeted.

The type of response immunotherapy provokes seems to depend on the approach and the type of tumor in question, the researchers agreed. Earlier stage tumors might respond better than later stage and some types of cancer, such as melanoma and kidney cancer, might provoke a bigger response, Celis wrote. While many of the therapies are still in clinical trials, there are already some getting a long-lasting effect.

About a fourth of the melanoma patients who received Yervoy are still seeing a benefit more than four years later and the National Cancer Institute tweeted that some melanoma patients have been in remission more than 10 years after immunotherapy. Yale Cancer Center tweeted that it had a three-time melanoma patient that achieved a total response after immunotherapy.

Comments (1) Add comment
ADVISORY: Users are solely responsible for opinions they post here and for following agreed-upon rules of civility. Posts and comments do not reflect the views of this site. Posts and comments are automatically checked for inappropriate language, but readers might find some comments offensive or inaccurate. If you believe a comment violates our rules, click the "Flag as offensive" link below the comment.
galaxygrl 06/18/14 - 11:01 pm

My husband was treated for recurrent melanoma in 1996 at NIH. It was experimental and there was a 2% cure rate in the protocol. He is still alive today at 66 and wasn't suppose to live to be 49!

Back to Top
Search Augusta jobs
Top headlines
Arraignment coming Tuesday in Irish Travelers case
A total of 22 people - 20 identified as Travelers and two from Augusta - face racketeering charges under the federal Racketeer Influenced and Corrupt Organizations Act.